🚀 Research transfer at #LMU: millions in funding for innovative asthma therapy Great success for our spin-off RNhale! The company, co-founded by LMU pharmacist Olivia Merkel and led by CEO Benjamin Winkeljann, receives 2.5 million euros from the EIC - European Innovation Council. 🔬 The focus: Inhalable RNA therapeutics - a completely new, targeted treatment for asthma. The technology is based on nano-transporters that deliver medication precisely to the site of action. 💡 From research to practice: #RNhale wants to use the highly endowed EU grant to prepare the technology for testing in clinical trials and drive forward business development for market release. This innovation could not only help asthma patients, but also enable new treatments for other respiratory diseases. What a success: Research at LMU Munich creates direct added value for society! 🎉 📸: Prof. Dr. Olivia Merkel & CEO Benjamin Winkeljann 🔗 Find out more here: https://lnkd.in/dcpXZcCQ #LMUMunich #Innovation #Research #Startups #Pharma
That's great!
Congratulations on milestone achievement Benjamin Winkeljann and team
80,000 Germans suffer diabetic foot infections and associated amputations each year. This number is troubling for such a small country. Yet the medical community continues to believe antibiotics are the answer—when antibiotics obviously are not. Think different.
Congratulations.
Congrats! Well deserved!
Super! Congratulations dear Olivia Merkel and Benjamin Winkeljann
Congratulations, great achievement!
Congrats Benjamin and Olivia!
Associate Professor of Pharm.Sci., Mercer University College of Pharmacy, Drug pharma, Biologics product, Devices, Combination, IR, ER, Nano/MicroParticles Products, lung diseases, cancer and covid-19
1wCongratulations!